March 2 (Reuters) - EyeGate Pharmaceuticals Inc EYEG.O :
* Received additional development milestone from Valeant Pharmaceuticals (NYSE:VRX)
Luxembourg under co's license agreement with Valeant
* Says is eligible to receive milestone payments totaling up to $32.5 million
* Source text for Eikon Further company coverage EYEG.O